ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Washington D.C.-based The Weinberg Group Inc. The Weinberg Group is a leading provider of regulatory and compliance services to the pharmaceutical, biotech, and medical device industries. “We are excited to welcome The Weinberg Group into the ProPharma Group and Linden families,” said Michael Farah, Chairman of ProPharma Group and Partner at Linden Capital Partners. “This acquisition further solidifies ProPharma Group’s position as a leading, globally integrated pharmaceutical services platform with world class regulatory affairs and compliance services. We are confident the combination will accelerate ProPharma Group’s growth and enhance its reputation as a value-added partner to its clients.”
For more than 35 years, The Weinberg Group has used scientific and regulatory acumen to provide FDA-focused regulatory and compliance services, supplying its clients with viable and efficient development pathways and compliance solutions. With this acquisition, ProPharma Group’s service offering will expand to include highly specialized, U.S. based pre-approval/pre-clinical regulatory services, effectively establishing a true, end-to-end solution for its clients across the globe. “ProPharma was a natural fit for us,” said Matthew Weinberg, The Weinberg Group’s CEO. “Given both of our leading positions in the marketplace, adding our science-based regulatory and compliance skills to that of ProPharma Group’s provides all of our clients the ability to develop their products with both global and local outcomes in mind.”
ProPharma Group, a leading provider of compliance services, continues to expand its global presence, now with more than 1,100 employees across United States, Canada, Europe, Japan, and Australia. The Weinberg Group, with its professional team of regulatory experts and science-driven approach, aligns perfectly with ProPharma Group’s portfolio of high-value services for life science companies. The Weinberg Group’s leadership team brings an abundance of industry knowledge and expertise that complements ProPharma Group’s. Dawn Sherman, ProPharma Group CEO, said, “by joining forces, ProPharma Group now has the full complement of life science consulting, medical information, pharmacovigilance, and regulatory affairs expertise to serve our clients around the world, wherever they need us, and at whatever point in the lifecycle of their products.”
Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Gain an Industry Edge With Expertise From ProPharma Group
Get the latest insights and top tips from our experts, delivered right to your inbox.
Have a complex challenge?